Piper Sandler Sticks to Its Buy Rating for Minerva Surgical (UTRS)
TipRanksNov 14, 2023 07:36 ET
Piper Sandler Adjusts Minerva Surgical's Price Target to $1 From $5, Keeps Overweight Rating
MT NewswiresMay 3, 2023 10:48 ET
Piper Sandler Maintains Overweight on Minerva Surgical, Lowers Price Target to $1
BenzingaMay 3, 2023 09:31 ET
Piper Sandler Remains a Buy on Minerva Surgical (UTRS)
TipRanksMar 23, 2023 11:08 ET
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and Minerva Surgical (UTRS)
TipRanksSep 7, 2022 08:40 ET
Minerva Surgical (UTRS) Was Downgraded to a Sell Rating at J.P. Morgan
TipRanksAug 31, 2022 08:20 ET
Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Minerva Surgical (UTRS) and Nektar Therapeutics (NKTR)
TipRanksAug 29, 2022 08:35 ET
J.P. Morgan Downgrades Minerva Surgical (UTRS) to a Sell
TipRanksAug 16, 2022 08:35 ET
Minerva downgraded at JPMorgan citing lowered guidance
Seeking AlphaAug 10, 2022 11:56 ET
Minerva Surgical Is Maintained at Overweight by Piper Sandler
Dow JonesAug 10, 2022 07:17 ET
Minerva Surgical Price Target Cut to $5.00/Share From $6.00 by Piper Sandler
Dow JonesAug 10, 2022 07:17 ET
Piper Sandler Maintains Overweight on Minerva Surgical, Lowers Price Target to $5
Benzinga Real-time NewsAug 10, 2022 07:08 ET
Piper Sandler Adjusts Minerva Surgical's Price Target to $5 From $6, Reiterates Overweight Rating
MT NewswiresAug 10, 2022 05:17 ET
Minerva Surgical Cut to Underweight From Overweight by JP Morgan
Dow JonesAug 10, 2022 05:10 ET
Minerva Surgical analyst ratings
Benzinga Analyst RatingsAug 10, 2022 05:00 ET
No Data
No Data